ATE497765T1 - Pharmazeutische zusammensetzung enthaltend quinuclidin-3'-yl 1-phenyl-1,2,3,4,- tetrahydroisoquinolin-2-carboxylat zur behandlung der interstitiellen cystitis und/oder der abakteriellen prostatitis - Google Patents

Pharmazeutische zusammensetzung enthaltend quinuclidin-3'-yl 1-phenyl-1,2,3,4,- tetrahydroisoquinolin-2-carboxylat zur behandlung der interstitiellen cystitis und/oder der abakteriellen prostatitis

Info

Publication number: ATE497765T1
Authority: AT; Austria
Prior art keywords: tetrahydroisoquinoline; carboxylate; phenyl; interstitial cystitis; treatment
Prior art date: 2001-07-10

Application number

AT02741446T

Other languages

English (en)

Inventor

Ken Ikeda

M Takeuchi

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-10

Filing date

2002-07-08

Publication date

2011-02-15

2002-07-08 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE497765T1 publication Critical patent/ATE497765T1/de

Links

208000005615 Interstitial Cystitis Diseases 0.000 title abstract 2
201000007094 prostatitis Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title 1
GQDSJYDRNIZSNY-UHFFFAOYSA-N 1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylic acid Chemical compound OC(=O)N1CCC2=CC=CC=C2C1C1=CC=CC=C1 GQDSJYDRNIZSNY-UHFFFAOYSA-N 0.000 abstract 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
210000001635 urinary tract Anatomy 0.000 abstract 2
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 abstract 1
206010015866 Extravasation Diseases 0.000 abstract 1
208000035154 Hyperesthesia Diseases 0.000 abstract 1
241000699670 Mus sp. Species 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
229960002504 capsaicin Drugs 0.000 abstract 1
235000017663 capsaicin Nutrition 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000000994 depressogenic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960003699 evans blue Drugs 0.000 abstract 1
230000036251 extravasation Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
210000005036 nerve Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Plant Substances (AREA)

AT02741446T 2001-07-10 2002-07-08 Pharmazeutische zusammensetzung enthaltend quinuclidin-3'-yl 1-phenyl-1,2,3,4,- tetrahydroisoquinolin-2-carboxylat zur behandlung der interstitiellen cystitis und/oder der abakteriellen prostatitis ATE497765T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001209041		2001-07-10
PCT/JP2002/006904 WO2003006019A1 (fr)	2001-07-10	2002-07-08	Composition medicinale destinee au traitement de la cystite interstitielle

Publications (1)

Publication Number	Publication Date
ATE497765T1 true ATE497765T1 (de)	2011-02-15

Family

ID=19044753

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02741446T ATE497765T1 (de)	2001-07-10	2002-07-08	Pharmazeutische zusammensetzung enthaltend quinuclidin-3'-yl 1-phenyl-1,2,3,4,- tetrahydroisoquinolin-2-carboxylat zur behandlung der interstitiellen cystitis und/oder der abakteriellen prostatitis

Country Status (19)

Country	Link
US (2)	US7335668B2 (de)
EP (1)	EP1405638B1 (de)
JP (1)	JP4174673B2 (de)
KR (1)	KR100874815B1 (de)
CN (1)	CN1270708C (de)
AT (1)	ATE497765T1 (de)
AU (1)	AU2002315814B2 (de)
BR (1)	BR0210873A (de)
CA (1)	CA2449922C (de)
CY (1)	CY1112600T1 (de)
DE (1)	DE60239134D1 (de)
DK (1)	DK1405638T3 (de)
ES (1)	ES2359719T3 (de)
MX (1)	MXPA04000124A (de)
PL (1)	PL208138B1 (de)
PT (1)	PT1405638E (de)
RU (1)	RU2290929C2 (de)
WO (1)	WO2003006019A1 (de)
ZA (1)	ZA200309632B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2558877A1 (en) *	2004-02-09	2005-08-18	Astellas Pharma Inc.	Solifenacin succinate-containing composition
JPWO2005087231A1 (ja) *	2004-03-16	2008-01-24	アステラス製薬株式会社	ソリフェナシン含有組成物
US7820690B2 (en) *	2004-03-19	2010-10-26	Solvay Pharmaceuticals Gmbh	Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
CN101601673B (zh) *	2004-03-25	2012-07-18	安斯泰来制药株式会社	用于固体制剂的索非那新或其盐的组合物
CZ23088U1 (cs)	2004-03-25	2011-12-19	Astellas Pharma Inc.	Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli
EP1775283A4 (de) *	2004-07-14	2008-12-10	Japan Tobacco Inc	3-aminobenzamid-verbindung und hemmer der aktivität des vanilloid-rezeptors 1 (vr1)
KR101042490B1 (ko) *	2004-07-15	2011-06-16	니뽄 다바코 산교 가부시키가이샤	축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
TWI356699B (en)	2004-11-10	2012-01-21	Kissei Pharmaceutical	Agent for treating interstitial cystitis and agent
EP1832288B1 (de) *	2004-12-27	2012-06-20	Astellas Pharma Inc.	Stabile granulatförmige pharmazeutische zusammensetzung von solifenacin oder seinem salz
CA2599158C (en) *	2005-02-25	2011-01-25	Astellas Pharma Inc.	Pharmaceutical agent comprising solifenacin
JP3701964B1 (ja) *	2005-03-08	2005-10-05	アステラス製薬株式会社	キヌクリジン誘導体の新規な塩
US7815939B2 (en)	2005-07-20	2010-10-19	Astellas Pharma Inc.	Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
JP4614084B2 (ja) *	2005-07-25	2011-01-19	アステラス製薬株式会社	キヌクリジン誘導体含有医薬組成物
CA2632508A1 (en)	2005-12-28	2008-06-05	Japan Tobacco Inc.	3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity
US7906508B2 (en) *	2005-12-28	2011-03-15	Japan Tobacco Inc.	3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
TWI482629B (zh) *	2008-07-01	2015-05-01	Tobishi Pharmaceutical Co	下泌尿道疾病治療劑及下泌尿道症狀改善劑
MD4025C2 (ro) *	2009-08-25	2010-10-31	Владимир КАРАУШ	Remediu pentru tratamentul prostatitei şi hiperplaziei prostatei
EP2818166A1 (de) *	2013-06-26	2014-12-31	Laboratorios del Dr. Esteve S.A.	Verwendung von sigma-Rezeptorliganden zur Vorbeugung und Behandlung von Schmerzen im Zusammenhang mit interstitieller Zystitis/Blasenschmerzsyndrom (IC/BPS)
DE102022104759A1 (de)	2022-02-28	2023-08-31	SCi Kontor GmbH	Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2696178B1 (fr) *	1992-09-30	1994-12-30	Sanofi Elf	Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
NO2005012I1 (no) *	1994-12-28	2005-06-06	Debio Rech Pharma Sa	Triptorelin og farmasoytisk akseptable salter derav
EP1011695B2 (de) *	1997-07-15	2009-11-04	The Regents of the University of Colorado	Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
CN1224384C (zh) *	1998-11-05	2005-10-26	大鹏药品工业株式会社	用于治疗排尿紊乱的治疗药物
CO5440228A1 (es) *	1999-08-23	2004-09-30	Lunbeck As H	Tratamiento de la incontinencia urinaria

2002
- 2002-07-08 AT AT02741446T patent/ATE497765T1/de active
- 2002-07-08 ES ES02741446T patent/ES2359719T3/es not_active Expired - Lifetime
- 2002-07-08 DE DE60239134T patent/DE60239134D1/de not_active Expired - Lifetime
- 2002-07-08 PT PT02741446T patent/PT1405638E/pt unknown
- 2002-07-08 CA CA002449922A patent/CA2449922C/en not_active Expired - Fee Related
- 2002-07-08 JP JP2003511825A patent/JP4174673B2/ja not_active Expired - Fee Related
- 2002-07-08 RU RU2004103746/15A patent/RU2290929C2/ru not_active IP Right Cessation
- 2002-07-08 EP EP02741446A patent/EP1405638B1/de not_active Expired - Lifetime
- 2002-07-08 KR KR1020047000284A patent/KR100874815B1/ko not_active Expired - Fee Related
- 2002-07-08 BR BR0210873-9A patent/BR0210873A/pt not_active IP Right Cessation
- 2002-07-08 MX MXPA04000124A patent/MXPA04000124A/es active IP Right Grant
- 2002-07-08 PL PL366731A patent/PL208138B1/pl not_active IP Right Cessation
- 2002-07-08 DK DK02741446.5T patent/DK1405638T3/da active
- 2002-07-08 ZA ZA200309632A patent/ZA200309632B/en unknown
- 2002-07-08 WO PCT/JP2002/006904 patent/WO2003006019A1/ja not_active Ceased
- 2002-07-08 AU AU2002315814A patent/AU2002315814B2/en not_active Ceased
- 2002-07-08 CN CNB028140303A patent/CN1270708C/zh not_active Expired - Fee Related
- 2002-07-08 US US10/479,798 patent/US7335668B2/en not_active Expired - Lifetime
2008
- 2008-01-03 US US12/003,908 patent/US20090105298A1/en not_active Abandoned
2011
- 2011-03-11 CY CY20111100272T patent/CY1112600T1/el unknown

Also Published As

Publication number	Publication date
BR0210873A (pt)	2004-06-22
RU2290929C2 (ru)	2007-01-10
WO2003006019A1 (fr)	2003-01-23
EP1405638B1 (de)	2011-02-09
US20040138252A1 (en)	2004-07-15
KR20040029358A (ko)	2004-04-06
CN1527708A (zh)	2004-09-08
ES2359719T3 (es)	2011-05-26
DK1405638T3 (da)	2011-04-18
RU2004103746A (ru)	2005-03-27
MXPA04000124A (es)	2004-05-21
PL366731A1 (en)	2005-02-07
JP4174673B2 (ja)	2008-11-05
US7335668B2 (en)	2008-02-26
AU2002315814B2 (en)	2007-05-31
PT1405638E (pt)	2011-04-06
KR100874815B1 (ko)	2008-12-19
CA2449922C (en)	2008-11-25
JPWO2003006019A1 (ja)	2004-10-28
ZA200309632B (en)	2004-12-22
CN1270708C (zh)	2006-08-23
CY1112600T1 (el)	2016-02-10
EP1405638A4 (de)	2006-04-12
CA2449922A1 (en)	2003-01-23
EP1405638A1 (de)	2004-04-07
US20090105298A1 (en)	2009-04-23
DE60239134D1 (de)	2011-03-24
PL208138B1 (pl)	2011-03-31

Legal Events

Date

Code

Title

Description

2011-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1405638

Country of ref document: EP

Publication	Publication Date	Title
DE60239134D1 (de)	2011-03-24	Pharmazeutische zusammensetzung enthaltend quinuclidin-3'-yl 1-phenyl-1,2,3,4,-tetrahydroisoquinolin-2-carboxylat zur behandlung der interstitiellen cystitis und/oder der abakteriellen prostatitis
ATE487493T1 (de)	2010-11-15	Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
ATE443043T1 (de)	2009-10-15	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE468137T1 (de)	2010-06-15	Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE423559T1 (de)	2009-03-15	Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
AU5584901A (en)	2001-10-30	Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
GB0318447D0 (en)	2003-09-10	Therapeutic agents
GB0225474D0 (en)	2002-12-11	Therapeutic agents
ATE396174T1 (de)	2008-06-15	Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
GB0228410D0 (en)	2003-01-08	Novel Compounds
PT1333887E (pt)	2006-10-31	Metodo de tratamento de desordens musculares
NO20063373L (no)	2006-09-21	CD40-antistoff-formuleringer og fremgangsmater
ATE236870T1 (de)	2003-04-15	Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen
MXPA03008623A (es)	2004-05-21	Combinacion farmaceutica para el tratamiento del cancer.
TR200100773T2 (tr)	2001-07-23	Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
ATE346614T1 (de)	2006-12-15	Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
EP1567641A4 (de)	2005-12-28	Proaerolysin enthaltende proteaseaktivierungssequenzen und verfahren zur anwendung bei der behandlung von prostatakrebs
ATE247709T1 (de)	2003-09-15	3'utr des menschliches prohibitin-gens
NO20054744L (no)	2005-10-14	Behandling av Alzheimers sykdom
BR0112212A (pt)	2003-12-30	Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes
EA200100009A1 (ru)	2002-02-28	Способ лечения сахарного диабета
DE60238408D1 (de)	2011-01-05	Antitumorale mittel
BRPI0410663A (pt)	2006-06-20	compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase
ATE446285T1 (de)	2009-11-15	Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
DE60214207D1 (de)	2006-10-05	Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis